Streetbeat News

LENZ

LENZ Therapeutics, Inc.

https://www.lenz-tx.com

Industry

Biotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Open

25.17

Mkt cap

700M

Volume

297K

High

25.65

P/E Ratio

-9.29

52-wk high

38.93

Low

24.78

Div yield

0.28

52-wk low

2.57

LENZ Therapeutics shares rise following positive Phase 3 trial results for LNZ100 in China, in collaboration with CORXEL.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 10:54 am

LENZ Therapeutics shares rose 18% in pre-market trading following positive Phase 3 trial results in China. Other notable pre-market movers include Healthcare Triangle, Pixie Dust Technologies, and Jet.AI, with significant gains, while SMX and Upexi saw declines.

Portfolio Pulse from Avi Kapoor

October 28, 2024 | 10:32 am

CORXEL and LENZ Therapeutics announced successful Phase 3 trial results for LNZ100, a treatment for presbyopia, showing significant improvement in vision for participants.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 6:52 am

LENZ Therapeutics Inc (NASDAQ:LENZ) shares rose 2.6% after the FDA accepted its new drug application for LNZ100, targeting presbyopia. The FDA decision is expected by August 2025, with no advisory committee meeting planned. The NDA is supported by positive Phase 3 results.

Portfolio Pulse from Henry Khederian

October 21, 2024 | 2:32 pm

LENZ Therapeutics shares rose following the FDA's acceptance of its new drug application for LNZ100, aimed at treating Presbyopia.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 1:44 pm

LENZ Therapeutics announced that the FDA has accepted its New Drug Application for LNZ100, a treatment for presbyopia. The FDA has set a target action date of August 8, 2025, and will not hold an advisory committee meeting.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:09 pm

LENZ Therapeutics shares rose following Raymond James' initiation of coverage with a Buy rating and a $37 price target.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 5:13 pm

Raymond James has initiated coverage on LENZ Therapeutics with an Outperform rating and set a price target of $37.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 5:09 pm

Piper Sandler analyst Joseph Catanzaro maintains an Overweight rating on LENZ Therapeutics (NASDAQ:LENZ) with a $36 price target.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 5:59 pm

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on LENZ Therapeutics (NASDAQ:LENZ) and maintained a price target of $38.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 10:51 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.